Analyze Association of BRCA2 Arg372His Polymorphism With Ovarian Cancer Risk.
Studies investigating the association between BRCA2 Arg372His polymorphism and ovarian cancer risks have yielded conflicting results. We carried out a meta-analysis of 8488 ovarian cancer cases and 14,510 controls from 7 case-control studies in 5 articles published. The association between BRCA2 Arg372His polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) appropriately derived from fixed effects models. There were no significant associations between BRCA2 Arg372His polymorphisms and ovarian cancer risk in overall comparisons in all genetic models (HH vs NN: OR, 1.06; 95% confidence interval [95% CI], 0.96-1.18; P = 0.25; NH vs NN: OR, 1.02; 95% CI, 0.96-1.07; P = 0.6; NH + HH vs NN: OR, 1.01; 95% CI, 0.98-1.04; P = 0.42; HH vs NN + NH: OR, 1.06; 95% CI, 0.95-1.17; P = 0.29). This meta-analysis indicates that the BRCA2 Arg372His polymorphism is not associated with ovarian cancer risk for whites. Asian and African populations should be further studied.